APA (7th ed.) Citation

C, F., G, Y., S, H., B, R., G, S., M, T., . . . J, K. (2022). Should HFrEF patients with NYHA class II expect benefit from CCM therapy? Results from the MAINTAINED observational study. Clinical research in cardiology : official journal of the German Cardiac Society, 111(11), 1286. https://doi.org/10.1007/s00392-022-02089-w

Chicago Style (17th ed.) Citation

C, Fastner, et al. "Should HFrEF Patients with NYHA Class II Expect Benefit from CCM Therapy? Results from the MAINTAINED Observational Study." Clinical Research in Cardiology : Official Journal of the German Cardiac Society 111, no. 11 (2022): 1286. https://doi.org/10.1007/s00392-022-02089-w.

MLA (9th ed.) Citation

C, Fastner, et al. "Should HFrEF Patients with NYHA Class II Expect Benefit from CCM Therapy? Results from the MAINTAINED Observational Study." Clinical Research in Cardiology : Official Journal of the German Cardiac Society, vol. 111, no. 11, 2022, p. 1286, https://doi.org/10.1007/s00392-022-02089-w.